SecBot SecBot
PRESS-RELEASE ·Filed Jul 2, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 1/10
Horizonimmediate Processed4mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Equity inducement grants of this size are standard practice and have no trading implications. Investors should focus on upcoming Phase 3 data for azetukalner in epilepsy and the MDD/BPD programs as key catalysts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$60.96
T+0 close · Jul 2, 2026 · via day close
Latest settled
−39.76%
T+60 · $36.72
Vs SPY
−43.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $60.96entry
  2. T+1 · 4mo ago −0.69%α −1.56% · $60.54
  3. T+5 · 4mo ago +16.40%α +15.47% · $70.96
  4. T+20 · 4mo ago +5.30%α +5.71% · $64.19
  5. T+60 · 7w ago −39.76%α −43.33% · $36.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equity awards under Nasdaq Rule 5635(c)(4), with an exercise price of $60.30 per share. The grants are routine retention tools for new hires and have negligible dilutive impact relative to the company's $5.8B market capitalization.

Key Facts

  • Aggregate grants: 20,200 share options and 11,850 RSUs to four new non-officer employees
  • Option exercise price: $60.30 per share, equal to July 1, 2026 closing price
  • Options vest 25% at one-year anniversary, then monthly over 4 years; RSUs vest 25% annually over 4 years
  • Grants approved by Compensation Committee as inducements material to employment per Nasdaq Rule 5635(c)(4)

Financial Impact

Total potential dilution of ~32,050 shares, representing approximately 0.05% of outstanding shares, immaterial

dilutionshare count

Risk Factors

  • No material risk, grants are routine and insignificant to valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3321547

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Viewing Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026